Inhibitors of PD-L1 (pembrolizumab), VEGFR (ramucirumab), and HER-2 (trastuzumab) have been verified to improve survival and prognosis in advanced ESCC and EAC. This evidence concerns the gene ERBB2 and esophageal squamous cell carcinoma.